Logo image of ICU

SEASTAR MEDICAL HOLDING CORP (ICU) Stock Fundamental Analysis

NASDAQ:ICU - Nasdaq - US81256L2034 - Common Stock - Currency: USD

1.81  +0.06 (+3.43%)

After market: 1.831 +0.02 (+1.16%)

Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to ICU. ICU was compared to 190 industry peers in the Health Care Equipment & Supplies industry. ICU may be in some trouble as it scores bad on both profitability and health. ICU has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

ICU had negative earnings in the past year.
ICU had a negative operating cash flow in the past year.
ICU Yearly Net Income VS EBIT VS OCF VS FCFICU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -5M -10M -15M -20M -25M

1.2 Ratios

The Return On Assets of ICU (-660.40%) is worse than 96.84% of its industry peers.
Industry RankSector Rank
ROA -660.4%
ROE N/A
ROIC N/A
ROA(3y)-665.26%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ICU Yearly ROA, ROE, ROICICU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 500 -500 1K 1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ICU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ICU Yearly Profit, Operating, Gross MarginsICU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

0

2. Health

2.1 Basic Checks

ICU has less shares outstanding than it did 1 year ago.
The debt/assets ratio for ICU is higher compared to a year ago.
ICU Yearly Shares OutstandingICU Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2M 4M 6M 8M 10M
ICU Yearly Total Debt VS Total AssetsICU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2M 4M 6M 8M

2.2 Solvency

Based on the Altman-Z score of -52.13, we must say that ICU is in the distress zone and has some risk of bankruptcy.
ICU's Altman-Z score of -52.13 is on the low side compared to the rest of the industry. ICU is outperformed by 92.63% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -52.13
ROIC/WACCN/A
WACCN/A
ICU Yearly LT Debt VS Equity VS FCFICU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 5M -5M -10M

2.3 Liquidity

A Current Ratio of 0.54 indicates that ICU may have some problems paying its short term obligations.
With a Current ratio value of 0.54, ICU is not doing good in the industry: 93.16% of the companies in the same industry are doing better.
A Quick Ratio of 0.54 indicates that ICU may have some problems paying its short term obligations.
ICU's Quick ratio of 0.54 is on the low side compared to the rest of the industry. ICU is outperformed by 93.16% of its industry peers.
Industry RankSector Rank
Current Ratio 0.54
Quick Ratio 0.54
ICU Yearly Current Assets VS Current LiabilitesICU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2M 4M 6M 8M 10M

1

3. Growth

3.1 Past

The earnings per share for ICU have decreased strongly by -16.00% in the last year.
EPS 1Y (TTM)-16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.78%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ICU will show a very strong growth in Earnings Per Share. The EPS will grow by 38.75% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y73.04%
EPS Next 2Y38.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ICU Yearly Revenue VS EstimatesICU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 200K 400K 600K 800K 1M
ICU Yearly EPS VS EstimatesICU Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 -5 -10 -15 -20 -25

1

4. Valuation

4.1 Price/Earnings Ratio

ICU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ICU. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ICU Price Earnings VS Forward Price EarningsICU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ICU Per share dataICU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

ICU's earnings are expected to grow with 38.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.75%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for ICU!.
Industry RankSector Rank
Dividend Yield N/A

SEASTAR MEDICAL HOLDING CORP

NASDAQ:ICU (3/7/2025, 8:00:02 PM)

After market: 1.831 +0.02 (+1.16%)

1.81

+0.06 (+3.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)04-14 2025-04-14/amc
Inst Owners2.52%
Inst Owner Change12.12%
Ins Owners1.11%
Ins Owner Change0.05%
Market Cap15.78M
Analysts80
Price Target7.14 (294.48%)
Short Float %4.31%
Short Ratio0.67
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.65%
Min EPS beat(2)3.62%
Max EPS beat(2)27.67%
EPS beat(4)2
Avg EPS beat(4)-15.42%
Min EPS beat(4)-67.56%
Max EPS beat(4)27.67%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-55.12%
Min Revenue beat(2)-100%
Max Revenue beat(2)-10.23%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 232.11
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-12.38
EYN/A
EPS(NY)-2.17
Fwd EYN/A
FCF(TTM)-1.81
FCFYN/A
OCF(TTM)-1.81
OCFYN/A
SpS0.01
BVpS-0.24
TBVpS-0.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -660.4%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-665.26%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.54
Quick Ratio 0.54
Altman-Z -52.13
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.78%
EPS Next Y73.04%
EPS Next 2Y38.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-341.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-341.31%
OCF growth 3YN/A
OCF growth 5YN/A